Recursion Pharmaceuticals (NASDAQ:RXRX) Issues Earnings Results, Hits Expectations

Recursion Pharmaceuticals (NASDAQ:RXRX) posted its quarterly earnings results on Monday. The company reported ($0.22) EPS for the quarter, meeting the consensus estimate of ($0.22), FiscalAI reports. Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. The firm had revenue of $18.55 million during the quarter, compared to analysts’ expectations of $14.81 million. During the same quarter in the prior year, the firm posted ($0.36) EPS.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.17 during trading on Wednesday, hitting $3.85. The company had a trading volume of 3,275,104 shares, compared to its average volume of 19,581,586. The company has a fifty day moving average price of $3.76 and a two-hundred day moving average price of $3.53. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.06 billion, a P/E ratio of -4.26 and a beta of 1.15. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $5.24.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on RXRX shares. Morgan Stanley set a $5.90 price objective on Recursion Pharmaceuticals in a research report on Friday, October 16th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Monday, October 19th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 17th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.18.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the stock in a transaction on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total transaction of $78,876.16. Following the completion of the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at $7,296,572.80. This represents a 1.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $5.00, for a total value of $125,000.00. Following the transaction, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. The trade was a 13.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 127,408 shares of company stock worth $546,076 over the last three months. Company insiders own 6.65% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.

Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.